Company: SISI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010889
Chunk: 190

Company: SHINECO, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 190
---
 benefit from continuing operations 
     (5,772,135) 
     (8,766,546) 
     2,994,411  
     (34.16)%
  
    Benefit for income taxes 
     (187,854) 
     (152,646) 
     (35,208) 
     23.07%
  
    Net loss from continuing operations 
     (5,584,281) 
     (8,613,900) 
     3,029,619  
     (35.17)%
  
    Net income (loss) from discontinued operations 
     (15,874,674) 
     4,531,193  
     (20,405,867) 
     (450.34)%
  
    Net loss 
    $(21,458,955) 
    $(4,082,707) 
    $(17,376,248) 
     425.61%
  
    Comprehensive loss attributable to Shineco Inc. 
    $(18,736,751) 
    $(2,199,618) 
    $(16,537,133) 
     751.82%

58

Revenue

Currently, we, through our PRC subsidiaries, have
two major business segments from continuing operations. First, developing, producing and distributing innovative rapid diagnostic and
other products and related medical devices for the most common diseases; this segment is conducted through Biowin. Second, developing
and selling healthy meals for people with slow metabolic health and those in recovery from metabolic disorders; this segment is conducted
through Fuzhou Meida.

The following table sets forth the breakdown of our
revenue for the nine months ended March 31, 2025 and 2024, respectively:

    Nine Months Ended March 31,  
    Variance 

    2025  
    %  
    2024  
    %  
    Amount  
    % 
  
    Rapid diagnostic and other products 
    $258,091  
     99.63% 
    $441,927  
     96.16% 
    $(183,836) 
     (41.60)%
  
    Healthy meal products 
     949  
     0.37% 
     17,645  
     3.84% 
     (16,696) 
     (